Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults with Inadequately Controlled Asthma with High Bronchodilator Reversibility

-Diagnosis of asthma, and presently has reversibility over pre-bronchodilator forced expiratory volume in 1 second (FEV1) of ≥ 20% at screening -Percent of predicted FEV1 ≥ 40% and ≤ 80% at screening -Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000/μg/day fluticasone powder or equivalent -Ongoing asthma symptoms with asthma control questionnaire (ACQ) composite score at screening and baseline ≥ 1.5 points

-History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma -History of allergic bronchopulmonary aspergillosis -Respiratory infection within 4 weeks of screening or 1 week of baseline visit -Subject has known history of Crohn's disease -Subject has any other significant concurrent medical condition of laboratory abnormalities, as defined in the study protocol -Subject has previously used any anti-interleukin-17 (IL17) biologic therapy -Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study -Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile -Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS) -Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety